Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review

A tétel rövid nézete
dc.contributor.authorGoldštajn, Marina Šprem
dc.contributor.authorMikuš, Mislav
dc.contributor.authorFerrari, Filippo Alberto
dc.contributor.authorBosco, Mariachiara
dc.contributor.authorUccella, Stefano
dc.contributor.authorNoventa, Marco
dc.contributor.authorTörök, Peter
dc.contributor.authorTerzic, Sanja
dc.contributor.authorLaganà, Antonio Simone
dc.contributor.authorGarzon, Simone
dc.contributor.authorTörök Péter (1975-) (szülész-nőgyógyász)
dc.contributor.submitterdepSzülészeti és Nőgyógyászati Intézet -- 40
dc.contributor.submitterdepÁOK
dc.contributor.submitterdepDebreceni Egyetem
dc.date.accessioned2023-07-17T13:21:35Z
dc.date.available2023-07-17T13:21:35Z
dc.date.oa2023-08-07
dc.date.updated2023-07-17T13:21:34Z
dc.description.abstractPurpose To summarize available evidence comparing the transdermal and the oral administration routes of hormone replacement therapy (HRT) in postmenopausal women. Methods We performed a systematic review of the literature on multiple databases between January 1990 and December 2021. We included randomized controlled trials and observational studies comparing the transdermal and oral administration routes of estrogens for HRT in postmenopausal women regarding at least one of the outcomes of interest: cardiovascular risk, venous thromboembolism (VTE), lipid metabolism, carbohydrate metabolism, bone mineral density (BMD), and risk of pre-malignant and malignant endometrial lesions, or breast cancer. Results The systematic literature search identified a total of 1369 manuscripts, of which 51 were included. Most studies were observational and of good quality, whereas the majority of randomized controlled trials presented a high or medium risk of bias. Oral and transdermal administration routes are similar regarding BMD, glucose metabolism, and lipid profile improvements, as well as do not appear different regarding breast cancer, endometrial disease, and cardiovascular risk. Identified literature provides clear evidence only for the VTE risk, which is higher with the oral administration route. Conclusions Available evidence comparing the transdermal and oral administration routes for HRT is limited and of low quality, recommending further investigations. VTE risk can be considered the clearest and strongest clinical difference between the two administration routes, supporting the transdermal HRT as safer than the oral administration route.
dc.description.correctorkzs
dc.identifier.citationArchives Of Gynecology And Obstetrics. -307 : 6 (2022), p. 1727-1745. -Arch. Gynecol. Obstet. -0932-0067. -1432-0711
dc.identifier.doi10.1007/s00404-022-06647-5
dc.identifier.issn0932-0067. -
dc.identifier.issn1432-0711
dc.identifier.opachttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM113479
dc.identifier.urihttps://hdl.handle.net/2437/357618
dc.identifier.urlhttps://link.springer.com/10.1007/s00404-022-06647-5
dc.languageeng
dc.rights.accessopen access article
dc.rights.ownerszerző
dc.subject.otheridegen nyelvű folyóiratközlemény külföldi lapban
dc.titleEffects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
FILE_UP_1_Effects of transdermal versus oral hormone replacement therapy in postmenopause a systematic review.pdf
Méret:
1.54 MB
Formátum:
Adobe Portable Document Format
Leírás:
kiadói változat
Letöltés
Gyűjtemények
Publikációs Adatbázis